Key facts
- This page summarizes Brian J. Donnelly's Form 4 filing for MYRIAD GENETICS INC (MYGN).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Sep 2026, 16:17.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
Additional SEC filing notes
Section 16 status
Brian J. Donnelly is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones.
SEC remarks
This "Exit" Form 4 is voluntarily filed to report solely that, effective on September 16, 2026, the Reporting Person no longer serves in the role of Chief Commercial Officer of the Company, and therefore is no longer subject to Section 16 reporting.